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 Cardiovascular and pulmonary diseases are leading causes of morbidity and mortality 
worldwide. Studies report an inverse correlation between levels of serum high-density lipoprotein 
(HDL) and the severity of cardiovascular and lung diseases. HDL has also been shown to be anti-
inflammatory, anti-atherosclerotic, and anti-oxidative. HDL’s cardioprotective functions are well 
understood through the reverse cholesterol transport process.  However, how HDL effects the 
immune system in the lungs is still unknown.  We hypothesize that HDL is critical in preventing 
pulmonary injury from lipopolysaccharide (LPS) through inhibiting neutrophil (PMN) 
chemotaxis. While HDL is known to be biologically protective, it has also been reported that HDL 
can become dysfunctional (D-HDL) in chronic inflammatory diseases. HDL is characterized as 
dysfunctional when it does not perform its protective mechanisms. It has been challenging to study 
D-HDL, in part, because D-HDL is found in specific patient populations commonly burdened with 
comorbidities and subsequent medications. Apolipoprotein A-I (apoA-I), the major protein 
component of HDL, is primarily responsible for HDL’s beneficial properties. There are apoA-I 
mimetic peptides, such as L-4F, available to study the biological properties of HDL in both in vitro 
and in vivo models. However, there is no such research tool available to study D-HDL. Therefore, 
to better understand how D-HDL differs from HDL, we also sought to design a D-HDL mimetic 





























































Presented to the Faculty of the Department of Engineering 
 







In Partial Fulfillment of the Requirements for the Degree  
 






























































































Kymberly Gowdy, PhD 
 
 
COMMITTEE MEMBER: _______________________________________________________ 
Barbara Muller-Borer, PhD 
 
 
COMMITTEE MEMBER: _______________________________________________________ 
Loren Limberis, PhD 
 
 
COMMITTEE MEMBER: _______________________________________________________ 
Kim Kew, PhD 
 
 
COMMITTEE MEMBER: _______________________________________________________ 
Tonya Zeczycki, PhD 
 
 
CHAIR OF THE DEPARTMENT  
OF ENGINEERING: ____________________________________________________________ 
Barbara Muller-Borer, PhD 
 
 
DEAN OF THE  
GRADUATE SCHOOL: _________________________________________________________ 















First, I would like to express my deepest gratitude to my mentor, Dr. Kymberly Gowdy. 
Without her guidance, I never would have been able to accomplish a fraction of what I have 
achieved during my time at ECU. Dr. Gowdy’s patience, wisdom, and passion for her work have 
always been an inspiration for me. She has helped me learn how to grow from being a student in 
the classroom to becoming a critically thinking scientist in the lab. Her guidance has helped me 
develop the skills necessary to work in this field and has helped me to prepare for, and find, work 
after school. I would also like to thank the remainder of my committee members Dr. Barbara 
Muller-Borer, Dr. Loren Limberis, Dr. Kim Kew, and Dr. Tonya Zeczycki who have all been 
instrumental in helping me complete my graduate degree and to grow as a scientist.  
I also would like to thank everyone in Dr. Gowdy’s lab for all the time they have dedicated 
to helping me with my research, and teaching me about the science and techniques that I have used 
throughout my education. I am deeply grateful to Dr. Sky Reece, Dr. Brita Kilburg-Basnyat, Myles 
Hodge, Christine Psaltis, and Bin Lou for all the help they have given me.  
Additionally, I’d like to thank all of the collaborators who have contributed to my research. 
I have been truly impressed by the professors at ECU’s willingness to work together and support 
me through my research. The list of people to thank is far too long to write out, but in particular I 
have to thank Dr. Toby Allen for all of his help with the peptide synthesis component of my project.   
Lastly, I would like to thank my family for all of their support and guidance throughout 
these challenging past few years. I would never have been able to get this far without their endless 







TABLE OF CONTENTS 
 
LIST OF FIGURES ....................................................................................................................... ix 
LIST OF ABBREVIATIONS ......................................................................................................... x 
CHAPTER I: INTRODUCTION .................................................................................................... 1 
Introduction ................................................................................................................................. 1 
The innate immune response during chronic inflammation ....................................................... 2 
High-Density Lipoprotein ........................................................................................................... 3 
HDL in reverse cholesterol transport .......................................................................................... 4 
The cardioprotective role of HDL............................................................................................... 4 
The pulmonary protective role of HDL ...................................................................................... 5 
Apolipoprotein A-I...................................................................................................................... 6 
ApoA-I mimetic peptides ............................................................................................................ 7 
Dysfunctional HDL ..................................................................................................................... 8 
Goal of research and statement of hypothesis ............................................................................. 9 
Specific aims ............................................................................................................................. 10 
CHAPTER II: A NOVEL ROLE FOR HDL IN PULMONARY IMMUNITY .......................... 11 
INTRODUCTION .................................................................................................................... 11 
METHODS ............................................................................................................................... 13 
Murine HDL pretreatment and whole body LPS exposure. .................................................. 13 
Murine sample collection. ..................................................................................................... 14 
Assessment of airspace inflammation and cholesterol content. ............................................ 14 
Pro-inflammatory cytokines, chemokines, and lipoprotein receptors expression in the lung.





Blood flow cytometry ............................................................................................................ 15 
Statistical analysis.................................................................................................................. 16 
RESULTS ................................................................................................................................. 16 
HDL suppresses LPS induced pulmonary neutrophils and macrophages ............................. 16 
LPS-increased airway protein concentration was not suppressed by HDL ........................... 16 
HDL inhibits select LPS induced pro-inflammatory cytokines............................................. 17 
HDL decreases PMN migration adhesion molecules ............................................................ 17 
HDL blunts LPS-induced upregulation of PMN chemotaxis receptor, CXCR2 ................... 18 
LPS exposure increases pulmonary cholesterol content ........................................................ 19 
HDL suppresses lipoprotein receptors after exposure to LPS ............................................... 19 
DISCUSSION ........................................................................................................................... 20 
FIGURES .................................................................................................................................. 25 
Figure 2.1 ............................................................................................................................... 25 
Figure 2.2 ............................................................................................................................... 26 
Figure 2.3 ............................................................................................................................... 27 
Figure 2.4 ............................................................................................................................... 28 
Figure 2.5 ............................................................................................................................... 29 
Figure 2.6 ............................................................................................................................... 30 
Figure 2.7 ............................................................................................................................... 31 
CHAPTER III: ENGINEERING A NOVEL DYSFUNCTIONAL HDL MIMETIC PEPTIDE. 32 
INTRODUCTION .................................................................................................................... 32 
METHODS ............................................................................................................................... 34 





Murine HDL pretreatment, whole body LPS exposure, and sample collection. ................... 35 
Endothelial cell culture and exposures. ................................................................................. 35 
Wound healing assay. ............................................................................................................ 36 
Pro-inflammatory cytokine, and adhesion molecule expression in the lung. ........................ 36 
RESULTS ................................................................................................................................. 37 
HDL in vivo suppresses LPS-increased expression of adhesion molecules ......................... 37 
HDL suppresses LPS-induced inflammation of endothelial cells ......................................... 38 
L-4F mimics HDL’s ability to suppress LPS-induced inflammation of endothelial cells .... 38 
LPS suppresses wound healing of endothelial cells .............................................................. 39 
L-4F rescues endothelial cell wound healing from LPS-induced suppression ...................... 39 
A novel D-HDL mimetic peptide retains the alpha-helix of L-4F ........................................ 40 
DISCUSSION ........................................................................................................................... 40 
FIGURES .................................................................................................................................. 45 
Figure 3.1 ............................................................................................................................... 45 
Figure 3.2 ............................................................................................................................... 46 
Figure 3.3 ............................................................................................................................... 47 
Figure 3.4 ............................................................................................................................... 48 
Figure 3.5 ............................................................................................................................... 49 
Figure 3.6 ............................................................................................................................... 50 
CHAPTER IV: CONCLUSIONS AND FUTURE DIRECTIONS .............................................. 51 
CONCLUSIONS/DISSCUSION .............................................................................................. 51 
FUTURE DIRECTIONS .......................................................................................................... 54 




















































LIST OF FIGURES 
2.1  HDL suppresses lung macrophage and neutrophil populations after lung injury           (25) 
2.2  HDL does not suppress LPS-increased airway protein          (26) 
2.3  HDL suppresses select pro-inflammatory cytokines and PMN chemokines after lung 
injury by LPS                (27) 
2.4  HDL suppresses adhesion molecule expression after LPS exposure        (28) 
2.5  CXCR2 surface display, but not percent PMNs, is suppressed by HDL       (29) 
2.6  LPS exposure increases airway cholesterol concentration         (30) 
2.7  HDL suppresses LPS-increased lipoprotein receptor gene expression       (31) 
3.1 HDL suppresses LPS-induced inflammation in the lungs          (45) 
3.2  HDL suppresses LPS-induced inflammation in endothelial cells        (46) 
3.3  L-4F suppresses LPS-induced inflammation in endothelial cells        (47) 
3.4  LPS suppressed endothelial cell wound healing at 1 μg/ml          (48) 
3.5  L-4F abrogates LPS-suppressed endothelial cell wound healing        (49) 










LIST OF ABBREVIATIONS 
 
AAT  α-1 antitrypsin 3 
ABCA1 ATP binding cassette transporter A-1 4 
ABCG1 ATP binding cassette transporter G-1 4 
Apo Apolipoprotein 3 
BALF Bronchoalveolar lavage fluid 14 
CD11b Cluster of differentiation molecule 11b 5 
CD14 Cluster of differentiation molecule 14 2 
Ct Cycle threshold 15 
CVD Cardiovascular disease 4 
CXCR2 C-X-C motif chemokine receptor 2 12 
DAMP  Damage associated molecular pattern 2 
D-HDL Dysfunctional high-density lipoprotein 8 
G-CSF  Granulocyte colony-stimulating factor 6 
HDL High-density lipoprotein 1 
HDL-C High-density lipoprotein-cholesterol 4 
HOCl  Hypochlorite 40 
HUVEC Human umbilical vein endothelial cell 5 
ICAM-1 Intracellular adhesion molecule-1 5 
IL-1β Interleukin-1β 2 
IL-6  Interleukin-6 2 
KC Keratinocyte chemoattractant 2 





LCAT Lecithin: cholesterol acetyltransferase 3 
LDL Low-density lipoprotein 5 
LDLr Low-density lipoprotein receptor 15 
LPS  Lipopolysaccharide 2 
LXR  Liver-X-receptor 52 
MALDI-TOF Matrix assisted laser desorption/ionization time of flight mass 
spectrometry 
53 
MCP-1 Monocyte chemoattractant protein-1 6 
MIP-2  Macrophage inflammatory protein-2 2 
MPO Myeloperoxidase 43 
MyD88 Myeloid differentiation primary response protein 88 2 
MΦ Macrophage 25 
NF-κB  Nuclear factor-κB 2 
PAMP  Pathogen associated molecular pattern 2 
PLTP Phospholipid transfer protein 3 
PMN Neutrophil 2 
PON1 Paraoxonase-1 3 
RCT  Reverse cholesterol transport 4 
ROS Reactive oxygen species 2 
SR-BI Scavenger receptor class B-I 4 
TLR4 Toll-like receptor 4 2 
TNF-α  Tumor necrosis factor-α 2 
VCAM Vascular adhesion molecule 6 









Cardiovascular and lung diseases were reported to be two of the top three leading causes of death 
in the United States as of 2015 (1). These diseases are commonly driven by chronic inflammation 
which can lead to severe tissue injury. As research has been conducted, an emerging role for 
cholesterol in the pathogenesis of cardiovascular and pulmonary diseases has developed (2, 3). 
High-density lipoprotein (HDL), a cholesterol transporter, has been shown to be protective of the 
cardiovascular and respiratory systems (4-7). Cholesterol is essential in the body for integrity of 
cellular membranes, cellular signaling, steroid production, and as a form of energy (8, 9). 
However, excess levels of cholesterol termed ‘hypercholesteremia’ can be pathological in the 
pulmonary and circulatory system (10, 11). Therefore, balanced cholesterol homeostasis is 
necessary and, when thrown out of balance, can exacerbate chronic inflammation. This has driven 
a need for pharmaceuticals that balance cholesterol levels in the body, such as the use of statins. 
However, these treatments have not been effective in treating cardiovascular diseases (12). As a 
result, there has been a call for new therapeutic targets for balancing cholesterol in the body. HDL 
plays a critical role in the balance of cholesterol by transporting cholesterol out of the circulatory 
system (13). However, the connection between HDL’s ability to transport cholesterol and its 
protective of role is unknown. It is only understood that HDL carries cholesterol and has an anti-
inflammatory role in the immune system. Therefore, developing a better understanding of the role 
of HDL in the immune system is important for the development of better therapeutics for these 








The innate immune response during chronic inflammation 
 
Cardiovascular and pulmonary diseases are considered to be the result of chronic inflammation 
from an acute immune response to a stimulus (14-16). The innate immune system generally 
recognizes two types of stimuli, a damaged-associated molecular pattern (DAMP) or a pathogen-
associated molecular pattern (PAMP). Lipopolysaccharide (LPS) is an PAMP commonly used to 
induce acute and chronic inflammatory responses. LPS is a lipid found in the outer membrane of 
gram-negative bacteria (17). When LPS enters the body, it binds to LPS-binding protein (LBP). 
This catalyzes LPS binding to cluster of differentiation molecule 14 (CD14), a receptor commonly 
found on myeloid cells, facilitating the activation of toll-like receptor 4 (TLR4) (18). Once TLR4 
is activated, an extensive cascade is triggered beginning with myeloid differentiation primary 
response protein 88 (MyD88) and ending with nuclear factor-κB (NF-κB). NF-κB is the 
responsible for the transcription and release of chemokines such as keratinocyte chemoattractant 
(KC) and macrophage inflammatory protein-2 (MIP-2) in rodents, or interleukin-8 (IL-8) in 
humans. NF-κB also contributes to transcription of pro-inflammatory cytokines such as tumor 
necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) (19, 20). Because LPS 
so easily binds to LBP and triggers the TLR4 cascade, an overly amplified immunological response 
can occur at certain exposure concentrations (21). Hyperinflammation can then damage the local 
tissue due to increased neutrophilia, reactive oxygen species (ROS) production, and protease 
release. Increased blood flow to the site of inflammation also perpetuates the inflammatory 
response as more macrophages, neutrophils (PMNs), and pro-inflammatory cytokines accumulate 










HDL is an 8-10 nm particle composed of a core with cholesterol, cholesteryl ester, fatty acids, 
triglycerides, proteins, enzymes, and micro RNAs and a phospholipid monolayer membrane 
interwoven with several apolipoprotein(apo)s (23-25). HDL’s primary function is cholesterol 
transport and is understood to be protective in the cardiovascular and respiratory systems. There 
are two HDL subpopulations based on density, HDL2, and HDL3 with HDL2 being less dense and 
larger than HDL3 (26). ApoA-I is the primary structural protein of HDL which makes up 70% of 
its protein content (27, 28). The second major structural protein is apoA-II, making up 15-20% of 
total HDL protein (29). HDL’s remaining protein content is composed of several other 
apolipoproteins, enzymes, lipid transfer proteins, acute phase proteins, proteinase inhibitors and 
various other proteins (27). Notable proteins are lecithin: cholesterol acetyltransferase (LCAT), 
phospholipid transfer protein (PLTP), paraoxonase 1 (PON1), and α-1-antitrypsin (AAT). LCAT 
is necessary for the esterification of cholesterol as it is transferred from tissue to nascent HDL to 
form mature HDL (30). PLTP transfers phospholipids from triglyceride-rich lipoproteins to HDL 
and has also been shown to bind other lipids such as LPS (31). PON1 is an enzyme found in HDL 
that has been shown to be anti-atherosclerotic due to hydrolyzing specific oxidized phospholipids 
in lipoproteins (32, 33), and increasing HDL binding to foamy macrophages (34). AAT is an 
enzyme that neutralizes elastase, the proteinase enzyme released by PMNs during inflammation 
(35). These proteins and enzymes all contribute to the overall function of HDL in the body, whether 








HDL in reverse cholesterol transport 
 
The primary function of HDL is to perform reverse cholesterol transport (RCT) (30). RCT is the 
process in which HDL takes up cholesterol from the cells of peripheral tissues or lipid-laden 
macrophages and transports the cholesterol to the liver to produce sterols, steroids, glucocorticoids, 
or excrete the cholesterol. Cholesterol is effluxed from peripheral tissues by ATP binding cassette 
transporter A-1 (ABCA1) and is transported to pre-β HDL (nascent/immature HDL) which is 
synthesized in the liver. The cholesterol is then esterified by LCAT, making the cholesterol more 
hydrophobic and stable within the HDL particle. As pre-β HDL fills with cholesteryl ester, it grows 
to HDL3, where ATP binding cassette transporter G-1 (ABCG1), in addition to ABCA1, effluxes 
cholesterol from macrophages and transports it to HDL. HDL then grows to HDL2, the largest and 
least dense HDL molecule. The filled HDL particle then passively passes through circulation until 
reaching the liver. Once HDL reaches the liver, scavenger receptor B class I (SR-BI) binds to the 
HDL particle and transfers the cholesteryl ester into the liver (36, 37).  
 
The cardioprotective role of HDL 
 
HDL is most widely known for being protective in the cardiovascular system. There is an inverse 
relationship between plasma HDL and the severity of cardiovascular disease (CVD) (4, 5). The 
leading pathway in HDL’s protective function has generally been thought to be the result of HDL 
performing RCT (38). Through RCT, HDL takes up cholesterol from foamy macrophages that are 
attempting to destroy plaque lesions (39). As a result, HDL inhibits the development of 
atherosclerosis or other forms of CVD. It is for this reason that clinicians measure the concentration 
of systemic HDL-cholesterol (HDL-C) as a diagnostic measure of early CVD development. 





HDL has been shown to lower the susceptibility of low-density lipoprotein (LDL) oxidation which 
is pro-atherosclerotic (40, 41). Also, HDL carries another protein, sphingosine-1-phosphate, which 
facilitates nitric oxide production and facilitates vascular tone modulation and circulatory 
homeostasis (42). Additionally, HDL has been shown to inhibit neutrophil adhesion to and 
migration through endothelial cells by suppressing adhesion molecule surface display (43). The 
ability of HDL to suppress intracellular adhesion molecule-1 (ICAM-1) is thought to be the result 
of HDL carrying micro RNA miR-223, which blunts the expression of ICAM-1 (44, 45). HDL is 
also beneficial to endothelial cell proliferation and migration, increasing the wound healing of 
human umbilical vein endothelial cells (HUVECs) (46). It has also been described that HDL can 
inhibit the activation of monocytes due to the decreased display of cluster of differentiation 
molecule 11b (CD11b) (47, 48). Along with these anti-atherosclerotic and anti-inflammatory 
properties, HDL has also demonstrated anti-oxidative (49-51), and some anti-thrombotic (52, 53) 
functions.  
 
The pulmonary protective role of HDL  
 
While HDL is primarily understood as cardioprotective, recent literature has indicated a protective 
role for HDL in the lungs. It has been recently reported that low HDL-C levels are associated with 
the development of asthma in adolescents (6). Also, apoA-I deficiency, which essentially prevents 
HDL formation, induces increased oxidative stress, inflammation, collagen deposition, and airway 
hyperresponsiveness (7). These findings indicate HDL is necessary for fundamental lung function. 
Additional research has demonstrated that HDL also plays a significant role in the pulmonary 
inflammatory response. It was found that HDL will accumulate in the lungs in a mouse model of 





PMNs after ovalbumin-induced airway inflammation (55). In that study, pulmonary neutrophilia 
was then suppressed by administration of an anti-granulocyte colony-stimulating factor (G-CSF) 
antibody, indicating the necessity of apoA-I to suppress PMN production after pulmonary injury. 
Furthermore, excess apoA-I administration decreases pulmonary neutrophilia and collagen 
deposition after bleomycin challenge (55), pulmonary inflammation after LPS challenge (56), and 
pulmonary inflammation from house dust mite-driven asthma (57). Collectively, this research 
demonstrates the necessity of HDL, and its primary structural protein apoA-I, in the pulmonary 
immune response and its ability to inhibit that response when given in excess.  
 
Apolipoprotein A-I  
 
ApoA-I is the major structural protein of HDL. It is a 243 amino acid protein with an amphipathic 
alpha-helix structure (23). The amphipathic alpha-helix structure of apoA-I and other 
apolipoproteins allows for the formation of lipoproteins by providing a hydrophobic side to face 
lipids and a hydrophilic side to allow lipoproteins to be soluble. There are many apolipoproteins 
within HDL and other lipoproteins, but apoA-I is unique to HDL and thought to be responsible for 
HDL’s protective function (58). For example, apoA-I is primarily responsible for the activity of 
HDL in RCT. ApoA-I selectively interacts with lipoprotein receptors to efflux cholesterol from 
lipid-laden macrophages or peripheral tissue and take up cholesterol within HDL (59-63). ApoA-
I is also a cofactor for LCAT to esterify cholesterol and increase its hydrophobicity, stabilizing 
cholesterol within HDL (64). While this role of apoA-I in RCT makes apoA-I anti-atherosclerotic, 
there have also been many studies demonstrating delipidated apoA-I to have anti-inflammatory 
properties similar to HDL. ApoA-I was shown to inhibit nonocclusive carotid periarterial collar-





protein-1 (MCP-1) in rabbits (65). Additionally, in an LPS-induced inflammatory model, 
genetically transferred human apoA-I by adenoviral vector to mice increased mouse survival and 
suppressed TLR4 expression (66). PMN density and myeloperoxidase concentrations in the lungs, 
markers of TLR4 induced inflammation, were also suppressed by apoA-I. Continued research has 
implicated apoA-I to play a role in the immune response through TLR4. Completely delipidated 
apoA-I can initiate TLR4 activation and through MyD88-dependent and –independent pathways, 
can activate NF-κB, and induce cytokine production in macrophages (67). Taken together, this 
information suggests that apoA-I has the ability to directly influence components of the immune 
system including modulation of the TLR4 pathway. 
 
ApoA-I mimetic peptides 
 
Because of the anti-inflammatory properties of apoA-I, apoA-I mimetic peptides have been 
designed to replicate endogenous apoA-I. These peptides are unique sequences designed to 
replicate the class A amphipathic alpha-helix of apoA-I (68). The original apoA-I mimetic, 18A, 
was shown to replace 40% of apoA-I within HDL. The modified HDL was then shown to be 
equally effectual as unmodified HDL in acting as an LCAT substrate, indicating 18A sufficiently 
mimics the structural motif of apoA-I (69). 18A has since been altered to increase lipid affinity, 
and thus increase the solubilization of lipids and prevent atherosclerosis (70, 71). While these 
peptides have been shown to increase lipid affinity and more effectively induce cholesterol efflux, 
the high lipid affinity is associated with cytotoxicity because of adverse effects on the integrity of 
the plasma membrane (72). Consequently, more peptides have been designed to reduce general 
lipid affinity, but induced cholesterol efflux specifically through a lipoprotein receptor (73-75). 





amino-acid sequence with effective cholesterol efflux and anti-inflammatory properties (77-79). 
While these peptides have been primarily studied in the context of CVD, L-4F has also been shown 
to be protective in the lungs (80, 81). These peptides have been designed as tools to further study 




While HDL is generally necessary for lung/cardiovascular homeostasis and protection, it can 
become dysfunctional in individuals with chronic inflammatory diseases. Dysfunctional HDL (D-
HDL) is identified as being larger in size or as having decreased protective function. As a result, 
D-HDL is less anti-inflammatory (82), anti-oxidative (83), anti-apoptotic,  and anti-atherosclerotic 
(84). D-HDL develops in chronic inflammatory diseases such as coronary artery disease (85), type 
II diabetes mellitus (86), or obesity (87) due to the high levels of oxidative stress throughout the 
body in these diseases. D-HDL may also contribute to the development of lung diseases such as 
chronic obstructive pulmonary disease (88) or viral pneumonia (89). D-HDL has been shown to 
be unable to prevent LDL oxidation in woman with systemic lupus erythematosus (90). Also, D-
HDL from diabetics is unable to increase endothelial cell wound healing (84). The definition of 
D-HDL is unclear, with the notion of it not behaving as functional HDL being the primary 
stipulation. As a result, there are many forms of D-HDL. One can be found to have D-HDL in a 
circumstance as simple as having a greater density of the larger sized subpopulation of HDL 
(HDL2) in circulation (91). The smaller sized subpopulation of HDL (HDL3) has been reported to 
be more protective than HDL2 (92), however, this is somewhat controversial as there have been 
conflicting reports on this finding (93, 94). Another form of D-HDL occurs during the acute phase 





the cholesterol efflux, anti-inflammatory (96), and the anti-oxidative ability of HDL (97, 98). HDL 
can also become dysfunctional when apoA-I is glycated, which usually is found in type II diabetics 
(99). D-HDL by glycation has an impaired ability to induce monocyte cholesterol efflux (100) and 
suppress the inflammatory response of monocytes/macrophages to LPS (101). The most 
commonly studied (102), and ubiquitously identified, type of D-HDL is induced by oxidation of 
apoA-I. Oxidized HDL has been found in type II diabetes (86), coronary artery disease (103), 
obesity (87), chronic kidney disease (104), atherosclerosis (105), and after acute inflammation 
(89). Most research has discovered where D-HDL can be found, however, there is very little 
literature on the ramifications of developing D-HDL, particularly in pulmonary disease.  
 
Goal of research and statement of hypothesis 
 
The role of HDL in CVD has been studied for decades, however the role of HDL in pulmonary 
immunity is severely understudied. As described earlier, HDL is necessary for fundamental lung 
function, and is involved in the innate immune response of the lungs. Yet, how HDL is 
incorporated into lung function is unknown. With the lack of clarity for the role of HDL in 
pulmonary immunity, the consequences of D-HDL in the pulmonary immune response is even less 
understood. ApoA-1 has been shown to be critical in the protective role of HDL in the lung and, 
as a result, apoA-1 mimetic peptides have been designed to study HDL. However, there are 
currently no D-HDL mimetic peptides that could be used to study the consequences of D-HDL in 
cardiovascular or pulmonary disease pathogenesis. The goal of this project is to further elucidate 
the role of HDL in the pulmonary immune system, and to design a D-HDL mimetic peptide to be 
used as a tool to study D-HDL in the context of pulmonary inflammation that can drive the 







Aim 1: Determine if HDL protects the lungs from inflammation by decreasing PMN 
chemotaxis. Hypothesis: HDL decreases pulmonary inflammation by decreasing the display of 
CXCR2 on PMNs, thus inhibiting PMN chemotaxis and chemokine potency. 
A. Observe if HDL suppresses the LPS-induced increase in pulmonary neutrophilia 
and inflammation. 
B. Evaluate if HDL suppresses the LPS-induced increase in surface display of CXCR2 
on blood PMNs. 
C. Determine the impact of LPS and HDL on cholesterol transportation in the lungs. 
Aim 2: Develop a model for evaluating the functionality of a novel D-HDL mimetic peptide. 
Hypothesis: The apoA-I mimetic peptide, L-4F, will replicate the protective functions of HDL 
during endothelial cell inflammation. 
A. Reveal if HDL suppresses the LPS-induced increases in VCAM and ICAM-1 
expression on endothelial cells in vitro.  
B. Ascertain if L-4F mimics the protective properties of HDL on endothelial cells 






















Pulmonary diseases are the third leading cause of death in the United States, accounting 
for more than 30% of deaths in 2015 (106). Additionally, metabolic and cardiovascular diseases 
can contribute to pulmonary disease onset and progression (107, 108). It has long been appreciated 
that there is an inverse relationship between plasma high-density lipoprotein (HDL) and 
cardiovascular disease (CVD) (4, 5). Recently, it has been reported that there is a similar 
relationship between serum HDL-cholesterol and the severity of pulmonary diseases (109-111). 
However, the mechanistic interaction of HDL influencing the severity of lung disease is 
understudied. Therefore, it is critical to further understand how HDL interacts with the pulmonary 
immune system. 
Several pulmonary diseases, such as chronic obstructive pulmonary disease, are the result 
of continuous acute phase inflammation (16). The innate immune response is generally stimulated 
by damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns 
(PAMPs). A commonly used PAMP for inducing acute phase inflammation is a lipid known as 
lipopolysaccharide (LPS), which activates the immune system through the toll-like receptor 4 
(TLR4) pathway (17, 18). This pathway leads to the production of pro-inflammatory cytokines 
such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β), 
neutrophil (PMN) chemokines such as keratinocyte chemoattractant (KC) and macrophage 
inflammatory protein-2 (MIP-2), and adhesion molecules such as intracellular adhesion molecule 
1 (ICAM-1) and vascular cell adhesion molecule (VCAM) (19, 20, 112).  
During host defense, activated PMNs display a CD11b/CD18 complex (113-115). 





chemokine molecules to create a chemotactic gradient to communicate to immune cells in 
circulation (116). MIP-2 and KC are the ligands for the C-X-C Motif Chemokine Receptor 2 
(CXCR2) on PMNs (117), which facilitates PMN chemotaxis (118). Production of these molecules 
contribute to trafficking leukocytes to the cite of inflammation for the body to resolve the 
inflammatory stimulus. However, hyperinflammation can damage the local tissue due to increased 
neutrophilia, reactive oxygen species production (ROS), and protease release (119). Due to the 
severity of pulmonary diseases across the world, it is critical to further understand the pulmonary 
immune response. Through further understanding, better treatments can be developed to reduce 
the burden of pulmonary diseases on society.  
It has recently become understood that HDL plays a significant role in the pulmonary 
immune system (120). HDL is an 8-10 nm particle composed of a core with cholesterol, cholesteryl 
ester, fatty acids, triglycerides, proteins, enzymes, and micro RNAs and a phospholipid monolayer 
membrane interwoven with several apolipoproteins (23-25). The protective properties of HDL 
have primarily been attributed to its major structural protein, apolipoprotein A-I (apoA-I) (58). 
ApoA-I deficient mice have increased pulmonary inflammation, oxidative stress, collagen 
deposition, and airway hyperresponsiveness (7). HDL is also beneficial to the lungs by increasing 
type II alveolar cell proliferation (121). Additionally, isolated apoA-I protects mouse lungs from 
LPS-induced inflammation (56). Also, HDL has been shown to accumulate in the lungs of mice 
with induced pulmonary emphysema (54). Congruently, HDL has been shown to decrease ICAM-
1 and VCAM expression after tumor necrosis factor α (TNF-α) incubation in vitro (43).  
Many of HDL’s cardioprotective properties have been attributed to its role in reverse 
cholesterol transport (RCT) (36, 122).  During RCT, lipoprotein receptors ATP binding cassette 





B-I (SR-BI) transport cholesterol from tissues/cells to HDL (30, 36, 123, 124). These lipoprotein 
receptors used in RCT are expressed in the lung on type I and type II alveolar epithelial cells and 
alveolar macrophages (61, 125, 126). These receptors allow HDL to interact with the lungs 
directly, promoting the RCT of lipids from type I and type II alveolar epithelial cells and surfactant 
secretion (127, 128). In addition to RCT, lipoprotein receptors have been reported to be protective 
against lung injury and development of chronic lung diseases (129-132).  
The hypothesis of this study was that increasing circulating levels of HDL will mitigate 
pulmonary injury and inflammation through modulation of lipoprotein receptors. This study 
evaluated the mechanism of how circulating HDL can mitigate pulmonary inflammation utilizing 
a well characterized model of pulmonary inflammation (LPS-induced injury).  These data indicate 
that HDL inhibits the pulmonary inflammatory response by suppressing the chemotactic and 
transmigratory potential of blood PMNs. Additionally, these findings show that HDL abrogates 
pulmonary lipoprotein receptor expression during lung injury. To our knowledge, these findings 
are the first to implicate the ability of HDL to inhibit PMN chemotactic potential through the 




Murine HDL pretreatment and whole body LPS exposure. C57BL/6J (WT) male mice, 8-12 
weeks were purchased from Jackson Laboratories (Bar Harbor, ME). HDL was purchased from 
Kalen biomedical (Germantown, MD). Escherichia coli 0111:B4 LPS was from Sigma (St. Louis, 
MO). All experiments were performed in accordance with the Animal Welfare Act and the U.S. 
Public Health Service Policy on Humane Care and Use of Laboratory Animals after review by 





(40mg/kg), or phosphate buffered saline (PBS) through retro-orbital injection (200 μL) and then 
exposed to aerosolized LPS (300 μg/mL) or were unexposed. Mice were exposed to aerosolized 
LPS for 30 min and necropsied 2 or 24 hours after exposure. 
 
Murine sample collection. Mice were first anesthetized with 990 mg/kg ketamine and 10 mg/kg 
xylazine, and then euthanized by a bilateral thoracotomy. During necropsy, blood, bronchoalveolar 
lavage fluid (BALF), and lung tissue were collected. Blood was collected by puncturing the right 
atrium with a 25-gauge needle and collecting from venous flow. Three quarter BALF was collected 
by actively instilling and withdrawing 26.25 ml/kg(body wt) PBS three times from the right lung with 
the left lung clamped off. The left lung was then excised, flash frozen, and stored at -80°C.  
 
Assessment of airspace inflammation and cholesterol content. Cell differentials were 
performed as previously described (129). Total cholesterol content in BALF was measured using 
an Amplex Red cholesterol assay kit from ThermoFisher (Wilmington, DE). BALF protein was 
measured using a Pierce BCA Protein Assay Kit from ThermoFisher (Wilmington, DE) and 
microplate photometer set to 562 nm .   
 
Pro-inflammatory cytokines, chemokines, and lipoprotein receptors expression in the lung. 
The left lungs of mice were flash frozen and total RNA was isolated using a Qiagen RNeasy Mini 
Kit (Qiagen, Valencia, CA). Concentrations of RNA for each sample were determined using the 
NanoDrop 2000 (ThermoFisher Scientific, Wilmington, DE). RNA was reverse transcribed, using 
the High Capacity RNA-to-cDNA Kit or High Capacity cDNA Reverse Transcription Kit, and 





One-Step RT-PCR kit (ThermoFisher Scientific, Waltham, MA). RT-PCR was completed with the 
Taqman Universal PCR Master Mix from Thermofisher (Waltham, MA). Taqman primers were 
obtained from Invitrogen (Waltham, MA). Primers used for RT-PCR were 18s (Mm03928990), 
Abcg1 (Mm00437390), Abca1 (Mm00442646), Cd36 (Mm00432403), Scarb1 (Mm00450234), 
Ldlr (Mm01177349), Cxcl2 (Mm00436450), Cxcl1 (Mm04207460), IL-1β (Mm00434228), TNF 
(Mm00443258), IL-6 (Mm00446190), ICAM-1 (Mm00516023), and VCAM (Mm01320970) 
from Thermofisher (Waltham, MA). Genes were amplified and detected using a ViiA 7 RT-PCR 
System (ThermoFisher, Waltham, MA) to obtain cycle threshold (Ct) values for target and internal 
reference cDNA levels. Fold changes in expression for mRNA quantities were calculated using 
the 2-ΔΔCt method and Ct values. Samples were normalized to 18S as previously described (133). 
Taqman primers identified pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) PMN chemokines 
(MIP-2, and KC) and lipoprotein receptors (ABCA1, ABCG1, SR-BI, Cluster of Differentiation 
36 (CD36), and LDL receptor (LDLr)) gene expression. 
 
Blood flow cytometry. During necropsy, blood was collected into EDTA tubes. Cells were 
blocked using 5% normal mouse serum and 5% normal rat serum (Jackson ImmunoResearch 
Laboratories Inc, West Grove, PA), and 1% Fc-receptor-block (anti-mouse CD16/32; eBioscience, 
San Diego, CA), and then stained with anti-mouse antibodies for anti-Ly6G-APC, anti-C-X-C 
Motif Chemokine Receptor 2 (CXCR2)-PerCp, anti-CD45-Pacific Blue, and anti-cluster of 
differentiation molecule 11B (CD11b)-BUV. Antibodies used were from Biolegend (San Diego, 
CA). Laser refraction was measured (BD LSRII flow cytometer) and analyzed using FlowJo 






Statistical analysis. Data were analyzed using parametric or nonparametric one-way ANOVA 
(Kruskal-Wallis test) followed by comparison using a Dunn’s multiple comparisons test to correct 
for multiple comparisons using statistical hypothesis testing in GraphPad Prism 7.0 (San Diego, 
CA). Where deemed appropriate, unpaired nonparametric t-test (Mann-Whitney tests) were 




HDL suppresses LPS induced pulmonary neutrophils and macrophages  
 
LPS exposure has been shown to induce pulmonary inflammation (18), which is inhibited by 
apoA-I and apoA-I mimetic peptides (56, 81, 121). However, the anti-inflammatory effects of 
HDL in the context of aerosolized LPS-induced acute lung injury has not been studied. Mice were 
pretreated with HDL retro-orbitally, then challenged with aerosolized LPS to induce an acute 
pulmonary inflammatory response. 24 hours after pretreatment and challenge, cell differentials 
from BALF were analyzed (Figure 2.1). HDL pretreatment alone did not alter pulmonary 
inflammation in unexposed mice. LPS exposure increased the number of airspace PMNs and 
decreased airspace macrophages. HDL pretreatment before LPS exposure caused a decrease in 
airway PMNs and macrophages compared to LPS exposed mice. 
 
LPS-increased airway protein concentration was not suppressed by HDL 
 
LPS is known to increase markers of injury such as lung protein (134-137). Given HDL 
pretreatment prevented leukocyte influx into the lungs, it was of interest to determine if HDL 
influced lung injury. 24 hours after pretreating mice with HDL and exposing them to LPS, BALF 





protein when mice were unexposed. LPS exposure significantly increased lung protein. HDL 
pretreatment did not suppress the LPS-induced increase of protein in the lungs.  
 
HDL inhibits select LPS induced pro-inflammatory cytokines 
 
HDL has been reported to suppress circulating levels of pro-inflammatory cytokines IL-6 and 
TNF-α in various animal models and models of acute lung injury (138-140). Given that 
pretreatment with HDL suppressed LPS induced pulmonary neutrophilia, the influence of HDL on 
pro-inflammatory cytokine expression was determined. Mice pretreated with HDL and exposed to 
LPS were necropsied 2 h after exposure to assess the inflammatory response of pulmonary resident 
cells, or 24 h after exposure to observe peak lung inflammation (141). RNA was isolated from 
whole lung tissue and expression of pro-inflammatory cytokines IL-6, TNF-α, IL-1β, and PMN 
recruiting chemokines MIP-2, and KC were measured by RT-PCR 2 and 24hrs post exposure 
(Figure 2.3). Pro-inflammatory cytokines and chemokines were unaffected by HDL in unexposed 
mice. After LPS exposure, all measured genes were upregulated both 2 and 24 hours after exposure 
compared to respective controls. Pro-inflammatory cytokine TNF-α was unaffected by HDL 
pretreatment 2 and 24 hours after LPS exposure. IL-6 was inhibited in HDL pretreated mice 2 
hours after LPS exposure and IL-1β 24 hours after LPS exposure. However, MIP-2 expression was 
suppressed by HDL 2 hours after LPS exposure, and KC was suppressed 2 and 24 hours after 
exposure.  
 
HDL decreases PMN migration adhesion molecules 
 
Downregulation of pulmonary PMNs and suppression of PMN chemoattractants suggested that 





of adhesion molecules ICAM-1 and VCAM, which are crucial for endothelial adhesion and 
transmigration (142), and have previously been shown to be suppressed by HDL (43). However, 
the effect of HDL on aerosolized LPS-induced expression of pulmonary ICAM-1 and VCAM has 
not been studied. mRNA gene expression of ICAM-1 and VCAM was measured by RT-PCR from 
the lungs of WT mice pretreated with HDL and exposed to LPS (Figure 2.4). HDL did not affect 
either adhesion molecule in unexposed mice. LPS exposure increased the expression of ICAM-1 
and VCAM 2 hours after injury. ICAM-1 and VCAM were not suppressed by HDL 2 hours after 
LPS exposure. 24 hours after LPS exposure, pulmonary ICAM-1 expression was increased. HDL 
pretreatment suppressed ICAM-1 and VCAM gene expression in the lungs 24 hours after LPS 
exposure.  
 
HDL blunts LPS-induced upregulation of PMN chemotaxis receptor, CXCR2 
 
Decreased pulmonary PMNs, PMN chemokines expression, and adhesion molecule expression 
suggests HDL would suppress PMN chemotaxis receptor, CXCR2; however, no report to which 
we are aware has demonstrated the effect of HDL on CXCR2 surface display on PMNs. Blood 
collected from HDL pretreated, and LPS exposed, mice was labeled with CD45, Ly6G, CD11b 
and CXCR2 antibodies and surface display on PMNs was observed by flow cytometry (Figure 
2.5). The percent of PMNs present in the blood (out of all hemopoietic cells) was suppressed in 
unexposed mice pretreated with HDL. LPS exposure did not cause a change in percent neutrophils. 
HDL pretreatment did not change percent neutrophils after LPS exposure. CD11b, a marker of 
PMN activation (113-115), was not altered by HDL pretreatment. Display of CXCR2 was 






LPS exposure increases pulmonary cholesterol content 
 
After finding HDL inhibits PMN chemotaxis during LPS exposure, we sought to begin to uncover 
the mechanism associated with this anti-inflammatory role in the lung. HDL is a cholesterol 
transporter, thus many of its protective functions are dependent on removing cholesterol from 
specific tissues. Since HDL modulates pulmonary cholesterol homeostasis and pulmonary 
inflammation, we evaluated the impact of HDL on the concentration of cholesterol in the BALF 
of LPS exposed mice. Surprisingly, we found that HDL pretreatment alone did not affect airspace 
cholesterol. LPS exposure significantly increased the concentration of total cholesterol in the 
lungs, which was then suppressed in HDL pretreated mice (Figure 2.6).  
 
HDL suppresses lipoprotein receptors after exposure to LPS 
 
HDL is actively involved in the transport of cholesterol via lipoprotein receptors such as ABCG1, 
ABCA1, and SR-BI. These receptors have also been tied to the pulmonary immune response in 
several studies (129, 131, 143). Because of these connections, the impact of HDL pretreatment on 
the gene expression of these receptors in the lungs of mice exposed to LPS was evaluated. The 
gene expression of CD36 was also observed because of its many overlapping roles with SR-BI 
(144), and LDLr expression was assessed because of its close relationship with HDL (145) (Figure 
2.7). HDL pretreatment alone had no effect on these lipoprotein receptors. LPS exposure caused a 
marked increase in gene expression of ABCG1, ABCA1, SR-BI, and LDLr 24 hours after, which 
was strongly suppressed by HDL pretreatment. CD36 was suppressed 24 hours after LPS exposure 
and suppressed further in HDL pretreated mice. There was also found to be an increase in gene 









Pulmonary diseases are serious conditions with considerable impact on current and future 
society. In 2010 lung diseases were reported to be the third leading cause of death worldwide 
(146). Medical costs associated with pulmonary diseases were reported to be $32.1 billion in 2010 
and are expected to rise to $49 billion by 2020 (147). As there is an inverse relationship between 
HDL-cholesterol and pulmonary diseases, advances in the understanding of HDL’s interaction 
with the pulmonary immune system may be necessary to alleviate some of the burden of 
pulmonary diseases across the world.  
 In this study it was demonstrated that HDL inhibits PMN chemotaxis in the lung after acute 
lung injury. This was concluded from finding that HDL suppressed pulmonary neutrophilia, PMN 
recruiting chemokines, and PMN chemokine receptor CXCR2. It was later demonstrated that this 
inhibition may be the result of a decreased cholesterol burden in the lungs due to the decreased 
pulmonary cholesterol content and lipoprotein receptor gene expression in the lung after HDL 
pretreatment. Overall, this report demonstrates a potential mechanistic outline of HDL’s role in 
pulmonary protection from acute lung injury.  
 To uncover the role of HDL in the pulmonary immune system, it was first demonstrated 
that HDL decreases pulmonary neutrophilia after LPS exposure, indicating an abrogation in the 
inflammatory response. However, it was found that HDL does not suppress airway protein 
concentration after LPS exposure. This indicates that alveolar damage was not prevented by HDL 
pretreatment. The inflammatory signaling response was then evaluated to determine the cause for 
decreased airway neutrophilia, but not decreased damage. The gene expression of pro-





inflammatory cytokines and PMN chemokines at 2 and 24 hours after injury was observed. By 
observing the response 2 hours after exposure, the responses of local resident cells were evaluated 
because there is minimal systemic migration to the site of injury after 2 hours. Consequently, 24 
hours after exposure peak leukocyte infiltration occurs (141), giving an indication of the complete 
inflammatory response. The only pro-inflammatory cytokine that was not affected by HDL was 
TNF-α. This is contradictory to previous studies; however, previous studies have used different 
routes of HDL delivery, LPS exposure, and animal models (56, 148-152). The early inhibition of 
IL-6 observed could suggest inhibition of resident alveolar macrophage activation and pro-
inflammatory response. IL-1β was only suppressed 24 hours after exposure in HDL pretreated 
mice, suggesting the pro-inflammatory state was becoming resolved after 24 hours in HDL 
pretreated mice. IL-6 can also play an anti-inflammatory role later after acute injury (153, 154), 
correlating with HDL pretreated mice having a resolving inflammatory state after 24 hours. 
Interestingly, PMN chemokines MIP-2 and KC were both suppressed 2 hours after LPS exposure. 
MIP-2 and KC are primarily secreted by macrophages, further supporting HDL effects alveolar 
macrophages early during injury (155, 156). KC also continued to be suppressed 24 hours after 
LPS exposure. The suppression of these PMN chemokines suggests a possible explanation to the 
decrease in pulmonary neutrophilia previously observed. Taken together, it appears HDL partially 
suppressed early secretion of pro-inflammatory cytokines, which lead to the suppression of 
alveolar macrophage mediated PMN recruitment.  
Additionally, the effect of HDL on PMN transmigratory potential was evaluated by 
measuring the expression of adhesion molecules ICAM-1 and VCAM in the lungs. It was found 
that HDL pretreatment suppresses the gene expression of ICAM-1 and VCAM in LPS exposed 





miR-223, which blunts the expression of ICAM-1 (44, 45). By inhibiting adhesion molecule 
expression, HDL effectively mitigated the ability of PMN’s to migrate into the lungs where 
chemokines would be secreted. The additional suppression of PMN chemokines with adhesion 
molecules leads to decreased chemotactic potential of PMNs during inflammation. Previously, 
HDL has indirectly been shown to influence leukocyte chemotaxis in pulmonary inflammation. 
Addition of an apoA-I mimetic peptide decreases PMN chemotaxis as well as CXCR2 surface 
display in apoA-I deficient murine PMNs (77). Also, isolated apoA-I has been shown to decrease 
monocyte chemotaxis in rabbits (157), and the number of BALF PMNs is increased in ovalbumin-
challenged apoA-I knockout mice when compared to ovalbumin-challenged WT mice (55). 
Additionally, HDL has been shown to decrease PMN migration to a sight of cardiac infarction in 
mice (158), indicating the potential to decrease PMN migration to the sight of injury in the lungs. 
This information was supported when it was observed that HDL pretreatment suppresses the 
surface display of CXCR2, but not percent PMNs after LPS exposure. This data suggests signaling 
for PMN production and activation was not inhibited by HDL pretreatment. However, PMN 
chemotactic potential through the endo/epithelium and into the lung was suppressed, possibly 
preventing pulmonary neutrophilia. If HDL prevents PMN transmigration through the 
endo/epithelium, then secretion of oxidative enzymes, ROS, and PMN phagocytosis would be 
prevented in the lungs which would reduce pulmonary inflammation.   
Knowing HDL can take up cholesterol from macrophages, we evaluated the cholesterol 
content in the lungs and found HDL slightly inhibits the LPS-induced increase of cholesterol in 
the lung BALF. The increase in cholesterol after LPS exposure may have been the result of 
systemic leak into the lung because of damaged alveoli from increased pulmonary neutrophilia. 





could then have been expanded by secreted ROS, and oxidative enzymes (159, 160). The decrease 
in observed cholesterol in the BALF might then be the result of an attenuated inflammatory 
response, and less damage to the alveolar membrane. Several studies have reported that the 
increased lipid raft formation that occurs in ABCG1 and ABCA1 deficient macrophages could 
account for enhanced inflammatory responses, especially after exposure to LPS (161-165). It is 
possible that the increased cholesterol deposition observed here during LPS injury exacerbated the 
inflammatory response. Additionally, ABCG1, ABCA1, and SR-BI have been shown to play a 
protective role in the lungs. ABCG1 deficient mice have been shown to have increased airway 
PMNs after ovalbumin sensitization and challenge (35). SR-BI deficient mice were also shown to 
have increased PMN recruitment and cytokine production in the airspace of lungs injured by 
bacterial pneumonia (33). ABCA1 has been shown to be activated by LPS exposure in THP-1 
monocytes and WT mice (54). Therefore, HDL pretreatment may have attenuated the 
inflammatory response by reducing the cholesterol burden on alveolar macrophages and 
consequently decreased PMN chemotaxis. To answer this question, the gene expression of 
cholesterol transporters and lipoprotein receptors ABCG1, ABCA1, SR-BI, CD36 and LDLr was 
measured. It was found that LPS significantly increased the expression of ABCG1, ABCA1, SR-
BI, and LDLr 24 hours after exposure. This expression was then suppressed by HDL pretreatment. 
We believe the increases in expression of the lipoprotein receptors was the result of cholesterol 
loading of alveolar macrophages after lung injury. When mice were pretreated with HDL, SR-BI 
was then responsible for transporting cholesterol from the alveolar macrophages to HDL 2 hours 
after exposure, thus reducing the cholesterol burden in the lungs. This reduced burden resulted in 






Overall, it has been demonstrated that HDL suppresses PMN chemotaxis by inhibiting 
MIP-2/KC production, suppressing adhesion molecules ICAM-1/VCAM production, and 
decreasing the surface display of CXCR2 on PMNs. It has also been shown that LPS exposure 
increases cholesterol content in the lungs and gene expression of several lipoprotein receptors. The 
increases in cholesterol and lipoprotein receptors was then suppressed by HDL. We have proposed 
a connection between these two phenotypes, stating increased cholesterol load on alveolar 
macrophages increases the inflammatory response, and HDL prevents that increased 
inflammation. With this information, treatments could be developed to target this anti-
inflammatory role of HDL in the pulmonary immune system to help alleviate the severity of 

































Figure 2.1 HDL suppresses lung macrophage and neutrophil populations after lung injury. Mice 
were pretreated with PBS or HDL retro-orbitally and exposed to aerosolized LPS or were 
unexposed and then necropsied 24 hours after exposure to measure BALF cell differentials. 
Macrophage (MΦ) and neutrophil (PMN) populations were recorded (n=5 per group; * p<0.05 


























Figure 2.2 HDL does not suppress LPS-increased airway protein. Mice were pretreated with HDL, 
exposed to LPS, and BALF was collected 24 hours after LPS exposure to measure BALF protein. 





























Figure 2.3 HDL suppresses select pro-inflammatory cytokines and PMN chemokines after lung 
injury by LPS. WT mice were pretreated with PBS or HDL and were then left unexposed or 
exposed to 300 μg/mL of LPS. 2h and 24h after LPS exposure, mice were necropsied. RNA was 
isolated from whole lung tissue and proinflammatory cytokines (A) TNF-a, (B) IL-6, (C) IL-1β 
and neutrophil chemoattractants (D) MIP-2 and (E) KC were measured by real time PCR. Data is 



























Figure 2.4 HDL suppresses adhesion molecule expression after LPS exposure. WT mice were 
pretreated with PBS or HDL and were then left unexposed or exposed to 300 μg/mL of LPS. 2h 
and 24h later, mice were necropsied. RNA was isolated from the lungs and adhesion molecules 
(A) ICAM-1 and (B) VCAM expression were measured by real time PCR. Data is presented as 



































Figure 2.5 CXCR2 surface display, but not percent PMNs, is suppressed by HDL. WT mice were 
pretreated with PBS or HDL and were then left unexposed or exposed to 300 μg/mL of LPS. 24h 
later, mice were necropsied. Blood was collected into EDTA tubes and labeled with Ly6g, CD45, 
CD11b, and CXCR2 antibodies and analyzed by flow cytometry. HDL pretreatment suppressed 
(A) scatter plot of percent PMN B) histogram of CXCR2 surface display (C) quantified percent 






















Figure 2.6 LPS exposure increases airway cholesterol concentration. WT mice were pretreated 
with PBS or HDL and were then left unexposed or exposed to 300 μg/mL of LPS. 2 and 24h later, 
BALF was analyzed for cholesterol content (measured by the Amplex Red Cholesterol Assay; n=5 






























Figure 2.7 HDL suppresses LPS-increased lipoprotein receptor gene expression. WT mice were 
pretreated with PBS or HDL and were then unexposed or exposed to 300 μg/mL of LPS. 2h and 
24h later, mice were necropsied. RNA was isolated from whole lung tissue and lipoprotein 
receptors (A) ABCG1, (B) ABCA1, (C) CD36 (D) SR-BI, and (E) LDLr expression was measured 
by real time PCR. Data is presented as ddCt compared to 18S (n=5 per group; * p<0.05 from PBS 
































 In 2015 pulmonary diseases contributed to almost 8% of reported deaths in the United 
States, ranking third behind cardiovascular disease and cancer (106). Pulmonary diseases are a 
continuously growing epidemic that have a severe impact on our current society. One avenue that 
has recently been pursued to develop therapies for these diseases is with high-density lipoprotein 
(HDL). There is an inverse relationship between HDL-cholesterol levels and the severity of 
pulmonary disease (109-111). Additionally, a potentially pathogenic post-translational 
modification to HDL, known as dysfunctional HDL (D-HDL), has been found in subjects with 
pulmonary disease (88). The repercussions of developing D-HDL could be severe, however, there 
are currently few effective methods to study the consequences of D-HDL in the lung. 
 HDL is an 8-10 nm cholesterol transporter composed of a core with cholesterol, cholesteryl 
ester, fatty acids, triglycerides, proteins, enzymes, and micro RNAs and a phospholipid monolayer 
membrane interwoven with several apolipoproteins (23-25). Many of HDL’s protective properties 
have been attributed to its role in reverse cholesterol transport (RCT) (36, 122).  During RCT, 
HDL takes up cholesterol from peripheral tissue and lipid-laden macrophages and transports that 
cholesterol to the liver for production of glucocorticoids, steroids, or excretion of cholesterol (36, 
37). This action gives HDL its anti-atherosclerotic properties. By removing cholesterol from lipid-
laden macrophages on atherosclerotic plaques (166), and altering the monocyte/macrophage lipid 
rafts (47), HDL inhibits vascular plaque buildup and inflammation. Along with this anti-
atherosclerotic role, HDL is also anti-inflammatory (167) anti-oxidative (49-51), and anti-





Many of HDL’s protective functions are thought to be attributed to HDL’s major structural 
protein, apolipoprotein A-I (apoA-I). ApoA-I is a 243 amino acid protein with an amphipathic 
alpha-helix structure (23). It makes up 70% of its protein content (27, 28), and selectively interacts 
with lipoprotein receptors to efflux cholesterol from lipid-laden macrophages or peripheral tissue 
and take up cholesterol within HDL (59-63, 168). Delipidated apoA-I has also been shown to be 
anti-inflammatory, suppressing tumor necrosis factor α (TNF-α), interleukin-1β, (IL-1β), 
interleukin-6 (IL-6), reactive oxygen species (ROS), intracellular adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule (VCAM), monocyte chemoattractant protein-1 (MCP-1), and toll-
like receptor 4 (TLR4) in various inflammatory models (56, 65, 66). ApoA-I mimetic peptides 
have been created to replicate the cholesterol efflux and anti-inflammatory abilities of endogenous 
apoA-I (69). These peptides are unique sequences designed to replicate the class A amphipathic 
alpha-helix of apoA-I (68). The most commonly studied apoA-I mimetic peptide is L-4F (76), 
which has been shown to effectively replicate the cholesterol efflux and anti-inflammatory 
properties of HDL (77-79).  
 HDL is normally protective in the body, however, in chronic inflammatory diseases HDL 
can become dysfunctional. D-HDL is identified as being larger in size or as having decreased 
protective function. As a result, D-HDL is less anti-inflammatory (82), anti-oxidative (83), and 
anti-atherosclerotic (84). The definition of D-HDL is unclear, with the notion of it not behaving as 
functional HDL being the primary stipulation. As a result, there are many forms of D-HDL. There 
can be an imbalance in HDL subpopulations (91), replacement of apoA-I with other proteins (95), 
glycation of apoA-I (99), or oxidation of apoA-I. The most commonly studied (102), and most 
ubiquitously identified, type of D-HDL is induced by oxidation of apoA-I. Oxidized D-HDL has 





disease (104), atherosclerosis (105), and after acute inflammation (89). This oxidation inhibits 
apoA-I’s endothelial repair (169), cholesterol transport (170), and anti-inflammatory properties 
(171), indicating oxidized HDL is dysfunctional. While the development of D-HDL has begun to 
become uncovered, the consequences of D-HDL in pulmonary diseases has yet to be elucidated.  
  Here in it was hypothesized that the apoA-I mimetic peptide, L-4F, would replicate the 
protective functions of HDL during endothelial cell inflammation. In this chapter, a model was 
established for reproducibly testing the mimicking ability of an apoA-I mimetic peptide and a D-
HDL mimetic peptide. Additionally, a D-HDL mimetic peptide (L-2W) was carefully designed to 
best reproduce the dysfunction of endogenous D-HDL. To our knowledge, this is the first D-HDL 
mimetic peptide that has been designed with the purpose of assessing the consequences of D-HDL 




Peptide synthesis. L-4F (Ac-DWFKAFYDKVAEKFKEAF-NH2) was synthesized using an 
automated solid phase synthesizer (PS3 from Protein Technologies Inc., Tucson, AZ). 
Fluorinylmethyloxycarbonyl (FMOC)-amino acids were coupled to a rink amide resin from 
Millipore Sigma (Burlington, MA) in the presence of 2-(H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU), and acetylated with acetic anhydride at the N-
terminus. The peptide was cleaved from the solid support using 90% TFA in the presence of 
anisole (5%) and triethylsilane (5%) during a 3-hour incubation, purified by high performance 
liquid chromatography (HPLC), lyophilized, and stored in a sealed container at room temperature. 






Murine HDL pretreatment, whole body LPS exposure, and sample collection. All experiments 
were performed in accordance with the Animal Welfare Act and the U.S. Public Health Service 
Policy on Humane Care and Use of Laboratory Animals after review by East Carolina University’s 
Animal Care and Use Committee. C57BL/6J (WT) male mice, 8-12 weeks were purchased from 
Jackson Laboratories (Bar Harbor, ME). HDL was purchased from Kalen biomedical 
(Germantown, MD). Escherichia coli 0111:B4 lipopolysaccharide (LPS) was from Sigma (St. 
Louis, MO). RNeasey minikit was from Qiagen (Germantown, MD). Mice were pretreated with 
HDL (40mg/kg), or PBS through retro-orbital injection (200 μL) and then exposed to aerosolized 
LPS (300 μg/mL) or room air (RA). Mice were exposed to aerosolized LPS for 30 min and 
necropsied 24 hours after exposure. Mice were anesthetized with 990 mg/kg ketamine and 10 
mg/kg xylazine, and then euthanized by a bilateral thoracotomy. During necropsy the left lung was 
excised, flash frozen, and stored at -80°C.  
 
Endothelial cell culture and exposures. Human umbilical vein endothelial cells (HUVECs) were 
purchased from Lonza (Morristown, NJ) and cultured in Endothelial Cell Medium from ScienCell 
Research Laboratories (Carlsbad, CA). Cells were cultured in T-75 culture flasks from 
ThermoFisher (Waltham, MA), or Falcon Tissue Culture Dish plates (100 x 20 mm) from Corning 
(Corning, NY). Cells were passaged until P5, P6, or P7 and stored in liquid nitrogen until use. 
After thawing, cells were passaged once and seeded in 12-well culture plates for about one day or 
until wells reached ~80% confluency, or if a monolayer was formed when desired. Cells were then 
incubated with PBS, HDL (200 μg/ml), or L-4F (50 μg/ml). Either at the same time, or 16-20 hours 
after incubation with PBS, HDL, or L-4F, cells were exposed to LPS (1 μg/ml or 0.1 μg/ml). Cells 






Wound healing assay. Cell migration ability can be determined by performing a wound healing 
migration assay (46). HUVECs were plated in 12-well plates with 1 ml of endothelial cell medium 
containing 1% fetal bovine serum and cultured until ~80% confluency or until monolayers formed. 
PBS, HDL (200 μg/ml), or L-4F (50 μg/ml) were incubated with the cells at ~80% confluency for 
16-20 hours before wounding, or treatments were incubated with the cells forming a monolayer 
immediately before wounding. Cells were then exposed to LPS (1 μg/ml or 0.1 μg/ml), and a 
wound was formed by scratching HUVECs with a 200 μl micropipette tip. Wound healing was 
observed by photographing the scratch with the EVOS FL Cell Imaging System 0, 4, 8, and 12 
hours after wounding. The width of the wound was measured at 6 locations per well using ImageJ 
software and a single averaged width per well was reported.  
 
Pro-inflammatory cytokine, and adhesion molecule expression in the lung. The left lungs of 
mice were flash frozen and total RNA was isolated using a Qiagen RNeasy Mini Kit (Qiagen, 
Valencia, CA). RNA was also collected from HUVECs. Concentrations of RNA for each sample 
were determined using the NanoDrop 2000 (ThermoFisher Scientific, Wilmington, DE). RNA was 
reverse transcribed, using the High Capacity RNA-to-cDNA Kit or High Capacity cDNA Reverse 
Transcription Kit, and real-time polymerase chain reaction (RT-PCR) was performed in a one-step 
reaction using iScript One-Step RT-PCR kit (ThermoFisher Scientific, Waltham, MA). RT-PCR 
was completed with the Taqman Universal PCR Master Mix from Thermofisher (Waltham, MA). 
Taqman primers were obtained from Invitrogen (Waltham, MA). Primers used for RT-PCR were 
18s (Mm03928990 or Hs03003631), Abcg1 (Mm00437390), Abca1 (Mm00442646), Cd36 





(Mm04207460), IL-1β (Mm00434228 or Hs01555410), TNF (Mm00443258 or Hs), IL-6 
(Mm00446190 or Hs00985639), ICAM-1 (Mm00516023 or Hs00164932), VCAM (Mm01320970 
or Hs01003372), and IL-8 (Hs00174360) from Thermofisher (Waltham, MA).  Genes were 
amplified and detected using a ViiA 7 RT-PCR System (ThermoFisher, Waltham, MA) to obtain 
cycle threshold (Ct) values for target and internal reference cDNA levels. Fold changes in 
expression for mRNA quantities were calculated using the 2-ΔΔCt method and Ct values. Samples 
were normalized to 18S as previously described (133). Taqman primers used were pro-




HDL in vivo suppresses LPS-increased expression of adhesion molecules 
 
There is currently no universal model in vitro used to test the functional ability of an HDL or D-
HDL mimetic peptide in relation to pulmonary disease. To determine which cell line to use in 
vitro, HDL’s ability to influence the lungs in vivo was evaluated. WT mice were pretreated with 
HDL retro-orbitally, then exposed to aerosolized LPS, and necropsied 24 hours after exposure. 
Whole lung tissue was excised, and RNA was collected to measure adhesion molecules ICAM-1, 
and VCAM gene expression by RT-PCR (Figure 3.1).  HDL pretreatment did not affect ICAM-1 
and VCAM levels before exposure. LPS exposure caused an increase in ICAM-1 gene expression. 
HDL pretreated and then LPS exposed mice had suppressed gene expression of ICAM-1 and 








HDL suppresses LPS-induced inflammation of endothelial cells 
 
HDL has been shown to suppress ICAM-1 and VCAM secretion from endothelial cells exposed 
to TNF-α (45, 172). Given that the data indicates that HDL can alter the expression of endothelial 
cell expressed adhesion molecules after pulmonary inflammation, endothelial cells were 
specifically assessed. HUVECs were incubated with HDL for 16 hours, exposed to LPS, and RNA 
was collected to measure ICAM-1, VCAM, and TNF-α by RT-PCR (Figure 3.2). HDL incubation 
alone had no effect on ICAM-1, VCAM, and TNF-α expression 16 hours after treatment. LPS 
exposure increased gene expression of ICAM-1, VCAM, and TNF-α. HDL incubation along with 
simultaneous LPS exposure suppressed gene expression of ICAM-1, VCAM, and TNF-α 
compared to LPS alone.  
 
L-4F mimics HDL’s ability to suppress LPS-induced inflammation of endothelial cells 
 
After demonstrating endothelial cells are suitable for the mimetic peptide testing model, L-4F’s 
ability to mimic HDL was assessed. L-4F has been shown to inhibit the production of ICAM-1, 
VCAM, and TNF-α from endothelial cells co-cultured with monocytes that had been pretreated 
with LPS (78). However, there is limited literature on the optimal LPS exposure concentration for 
assessing L-4F function on endothelial cells. Because of this, HUVECs were exposed to L-4F and 
LPS at 0.1 μg/ml or 1 μg/ml simultaneously (L-4F+LPS) for 12 hours and were collected to 
measure gene expression of ICAM-1, VCAM, and TNF-α by RT-PCR (Figure 3.3). L-4F alone 
did not affect expression. 0.1 μg/ml LPS increased gene expression for all markers, and 1 μg/ml 
of LPS increased gene expression more than 0.1 μg/ml of LPS. L-4F+LPS(1 μg/ml) cells had 
suppressed expression of ICAM-1, VCAM, and TNF-α and L-4F+LPS(0.1 μg/ml) cells had further 





LPS suppresses wound healing of endothelial cells 
 
HDL has been shown to increase endothelial cell wound healing (84), however, the effect of L-4F 
on HUVEC wound healing has not been assessed. Likewise, the impact of LPS on wound healing 
has been understudied. To uncover these effects, HUVECs were exposed to L-4F and LPS at 0.1 
μg/ml or 1 μg/ml, scratched, and photographed 0, 4, 8, and 12 hours after exposure. Percent wound 
closure after 12 hours was recorded (Figure 3.4). Cells exposed to PBS as a control averaged 89.8% 
wound closure 12 hours after scratching. L-4F did not alter wound healing. LPS exposure at 0.1 
μg/ml did not alter wound healing. LPS exposure at 1 μg/ml significantly suppressed wound 
healing 12 hours after exposure. Cells exposed to LPS+L-4F also had significantly suppressed 
wound healing 12 hours after exposure, indicating L-4F did not rescue wound healing.  
 
L-4F rescues endothelial cell wound healing from LPS-induced suppression 
 
Despite initially finding L-4F did not rescue wound healing, it seemed unlikely the apoA-I mimetic 
peptide would be unable to replicate the wound healing ability of HDL. L-4F has been shown to 
bind to LPS and suppress LPS induced inflammation (78), suggesting L-4F should inhibit the 
deleterious effects of LPS on wound healing. In one report, HDL has been shown to rescue wound 
healing after being incubated with cells 16 hours before TNF-α exposure (43). Therefore, 
HUVECs were incubated with L-4F 16 hours before LPS exposure, scratched, and wound healing 
was observed 12 hours later (Figure 3.5). L-4F alone did not influence endothelial wound healing. 
LPS exposure decreased wound healing. Cells incubated with L-4F for 16 hours and then exposed 







A novel D-HDL mimetic peptide retains the alpha-helix of L-4F 
 
Here in a model has been developed to assess the functionality of an HDL or D-HDL mimetic 
peptide. Subsequently, a D-HDL mimetic peptide has been designed to be used for studying the 
impact of developing D-HDL in the context of pulmonary disease. Due to the high propensity of 
oxidized D-HDL, oxidation of an apoA-I mimetic peptide is the foundation behind the novel 
peptide’s design. It was reported that hypochlorite (HOCl) oxidation of L-4F does not inhibit its 
ability to efflux cholesterol (173). Therefore, the novel D-HDL mimetic peptide was designed to 
increase L-4F’s susceptibility to oxidation. The novel mimetic, L-2W, was designed by 
substituting the carboxyl-terminal phenylalanine of L-4F for a tryptophan and oxidizing the 
peptide with HOCl (Figure 3.6A). This design was constructed to maintain the amphipathic alpha 
helix of L-4F before oxidation occurs. Using 3D molecular dynamics modeling, L-2W was shown 





Research on HDL has mostly been focused on its protective role in cardiovascular disease, 
however, there is a growing need to evaluate the role of HDL in the context of pulmonary disease 
(120). Along with the protective role of HDL in the lungs, the consequences of D-HDL in the 
lungs are critically important to understand. However, due to the heterogeneous nature of HDL 
(174, 175), and the variety of D-HDL that develops (91, 95, 99, 102), this pathologic condition is 
difficult to study. Because of these difficulties, the goal of this research is to develop a model for 
reproducibly testing the functionality of a HDL and D-HDL mimetic peptide. Furthermore, a D-





HDL in pulmonary diseases. With this goal in mind, it is hypothesized that the apoA-I mimetic 
peptide, L-4F, will replicate the protective functions of HDL on endothelial cells exposed to LPS. 
 A model was to be developed by identifying the parameters required for the HDL mimetic 
peptide, L-4F, to accurately mimic the protective functions of HDL. The first challenge was to 
determine what cell type in the lungs is consistently protected by HDL. It is known that HDL can 
interact with macrophages, endothelial cells, and epithelial cells in the lungs through lipoprotein 
receptors to transport cholesterol (61, 125, 126). Macrophages may be a suitable cell type to use 
for assessing HDL mimetic peptide function because of HDL’s ability to suppress their 
inflammatory response (176) and efflux cholesterol (177). However, delipidated apoA-I can cause 
a pro-inflammatory response in macrophages (67). This is contrary to the normal anti-
inflammatory role of HDL and requires more research to increase the understanding of HDL, thus 
making macrophages an unsuitable cell type for developing a model to assess HDL mimetic 
peptide function. Because of this, endothelial or epithelial cells were decided to be the more likely 
candidates to be used for developing an HDL mimetic peptide testing model. This was verified 
when WT mice were pretreated with HDL, exposed to LPS, and observed to have decreased 
adhesion molecule expression (ICAM-1, and VCAM) in isolated lung tissue. Endothelial cells 
were then selected over epithelial cells because HDL more commonly interacts with endothelial 
cells since it passes through circulation, there is no concern of air-liquid interface culturing, and 
HDL can increase wound healing of endothelial cells (84, 178). Endothelial cells were confirmed 
to be a suitable cell type when HUVECs had suppressed expression of adhesion molecules ICAM-
1, and VCAM when treated with HDL and LPS compared to LPS alone.  
 After establishing that HDL protects endothelial cells in vitro from LPS-induced 





concentration of LPS for assessing the anti-inflammatory ability of L-4F was evaluated because 
there is limited literature on the use of LPS in combination with L-4F with endothelial cells. It was 
reported that L-4F suppressed the gene expression of adhesion molecules, ICAM-1 and VCAM, 
as well as pro-inflammatory cytokine TNF-α. It was also shown that suppression was concentration 
dependent for LPS exposure, with the lower concentration of LPS (0.1 μg/ml) being suppressed 
more than the higher concentration of LPS (1 μg/ml). Consequently, there was not complete 
immunosuppression in the L-4F treated cells. This is likely the result of concentration dependent 
binding of L-4F to LPS. It was reported that L-4F likely binds LPS as L-4F incubated with LPS 
had a single size exclusion chromatographic peak distinct from individual LPS or L-4F peaks (78). 
It is likely that L-4F binds the lipid A moiety of LPS because of its anionic and amphipathic 
structure making an ideal target for L-4F binding (179). This binding would inhibit the LPS-
induced inflammatory response by competitively inhibiting the lipid binding protein (LBP)/cluster 
of differentiation 14 (CD14) complex necessary for activating the TLR4 inflammatory pathway 
(112, 180). Thus, by increasing the concentration of LPS from 0.1 μg/ml to 1 μg/ml without 
changing the concentration of L-4F, there was less competitive inhibition of LBP/CD14, and less 
suppression of inflammation.  
 Another method for determining HDL mimetic peptide functionality in this model is to 
assess the wound healing ability of the mimetic peptides. It has been well established that HDL 
increases endothelial repair, proliferation, and migration (46, 84, 178, 181-184). However, to the 
best of our knowledge, only one group has evaluated the endothelial repair abilities of L-4F, using 
human aorta endothelial cells (178). It was reported that L-4F did not increase HUVEC wound 
healing when incubated with endothelial cells for 12 hours. There has also been little research on 





shows controversial data of LPS either increasing or decreasing migration (185, 186). Therefore, 
the impact of LPS at 0.1 μg/ml or 1 μg/ml on wound healing of endothelial cells was assessed in 
the presence or absence of L-4F after 12 hours. LPS decreased wound healing at 1 μg/ml, which 
was not prevented by co-incubation with L-4F. After further investigation, it was found that 
incubation of L-4F with endothelial cells for 16 hours before LPS exposure and scratching rescued 
the decreased wound healing caused by LPS. This is a novel finding that requires further 
investigation because of the potential impact to cardiovascular and pulmonary diseases.  
 Once a model had been established for evaluating the functionality of HDL mimetic 
peptides, a D-HDL mimetic peptide could be designed. The idea behind the D-HDL mimetic 
peptide design was to create an oxidized HDL mimetic peptide since oxidized HDL is the most 
commonly studied type of D-HDL (102). HDL oxidation usually occurs, but not exclusively, 
through a reaction involving an enzyme secreted by PMNs and macrophages called 
myeloperoxidase (MPO) (105). MPO catalyzes a reaction utilizing hydrogen peroxide and a 
chlorine containing compound, such as sodium chloride, to produce HOCl (187). MPO has been 
shown to bind selectively to apoA-I on HDL, likely facilitating the oxidation of apoA-I from 
produced HOCl (188), which has been shown to occur on varying amino acids in apoA-I’s 
sequence (170, 189-191).  Oxidizing the currently studied apoA-I mimetic peptide, L-4F, is not 
enough to induce peptide dysfunction, as the oxidized peptide’s ability to induce cholesterol efflux 
on macrophages is preserved (173). However, it is still true that oxidation of apoA-I causes HDL 
dysfunction (169, 178, 189, 191, 192), therefore it is likely that increasing the susceptibility of the 
L-4F would induce peptide dysfunction. By increasing susceptibility of oxidation, the 
amphipathicity, and hydrophobicity of the peptide would be disrupted once oxidized, possibly 





oxidation was increased by substituting the carboxyl-terminal phenylalanine for tryptophan 
because tryptophan was the one amino acid oxidized when incubated with HOCl (173). The 
phenylalanine was chosen because tryptophan and phenylalanine have similar non-polar 
tendencies and have similar structural shapes. These similarities allow the substitution to occur 
without denaturing the amphipathic alpha-helix of all other apoA-I mimetic peptides. The terminal 
phenylalanine was also chosen to avoid denaturing, as a more central phenylalanine might have 
caused a kink in the peptide since tryptophan is slightly bulkier than phenylalanine. The new 
peptide, L-2W, was confirmed to retain the necessary alpha-helix structure by 3D molecular 
dynamic modeling. L-2W, a hypothetically functional peptide, could then be oxidized by HOCl 
and then become dysfunctional because of the increased susceptibility to oxidation. 
 In this study, a model has been developed to assess the functional capabilities of HDL or 
D-HDL mimetic peptides. It has been reported that HDL suppresses the LPS-induced expression 
of adhesion molecules in the lungs. HDL was confirmed to influence the endothelial cell 
inflammatory response to LPS in vitro, which was shown to be effectively mimicked by L-4F. The 
anti-inflammatory effect of L-4F was shown to be influenced by the concentration of LPS 
exposure. The concentration of LPS was also shown to influence wound healing of endothelial 
cells. Also, incubation period of L-4F before LPS exposure was shown to influence wound healing. 
By developing this model, the designed D-HDL mimetic peptide, or future HDL or D-HDL 
mimetic peptides, could be evaluated to test their functional capabilities. With these tools, the 
consequences of D-HDL in the context of pulmonary disease can be further understood. 
Furthermore, by understanding the consequences of D-HDL development, therapies for pulmonary 









Figure 3.1 HDL suppresses LPS-induced inflammation in the lungs. WT mice were pretreated 
with PBS or HDL and were then exposed to RA or 300 μg/mL of LPS. 24h later, mice were 
necropsied. Whole lung RNA was isolated and adhesion molecules (A) ICAM-1 and (B) VCAM 
expression were measured by RT-PCR. Data is presented as ddCt compared to 18S (n=5 per 



















Figure 3.2 HDL suppresses LPS-induced inflammation in endothelial cells. HUVECs were 
incubated with HDL (200 μg/ml) for 16 hours and exposed to LPS (1 μg/ml) for 12 hours. Cells 
were lysed and collected to measure RNA. Gene expression of A) ICAM-1, B) VCAM, and C) 
TNF-α was measured by RT-PCR. Data is presented as ddCt compared to 18S (n=3 per group; * 














Figure 3.3 L-4F suppresses LPS-induced inflammation in endothelial cells. HUVECs were 
exposed to L-4F (50 μg/ml) and LPS (0.1 μg/ml or 1 μg/ml) for 12 hours. Cells were then lysed 
and collected to measure gene expression of ICAM-1, VCAM, and TNF-α by RT-PCR. Data is 


























Figure 3.4 LPS suppressed endothelial cell wound healing at 1 μg/ml. HUVECs were exposed to 
L-4F (50 μg/ml) and LPS (0.1 μg/ml or 1 μg/ml), scratched with a 200 μl pipette tip, and imaged 
0, 4, 8, and 12 hours after exposure. Width of wound was measured by ImageJ, and percent wound 




















Figure 3.5 L-4F abrogates LPS-suppressed endothelial cell wound healing. HUVECs were seeded 
in a 12 well plate, and incubated with L-4F (50 μg/ml) after reaching ~80% confluency. 16 hours 
after incubation, cells were exposed to LPS (1 μg/ml) and scratched with a 200 μl pipette tip. Cells 
were then imaged 0, and 12 hours after exposure and percent wound closure was assessed using 




















Figure 3.6 A designed novel D-HDL mimetic peptide retains an alpha-helix. (A)L-2W was 
designed by substituting the carboxyl-terminus phenylalanine for a tryptophan and the D-HDL 
mimetic peptide was then designed by oxidizing L-2W with HOCl to make oxL-2W. (B) L-2W 









































This thesis contributes to developing a higher knowledge of the role of HDL in the 
pulmonary immune system and developing tools to study HDL and D-HDL in the lungs. In chapter 
II, HDL was reported to inhibit the chemotactic potential of PMNs while modulation of several 
lipoprotein receptors in the lungs was observed. This significant finding implicates the crucial role 
of HDL in the pulmonary immune response. In chapter III, a model was developed for testing the 
functionality of HDL or D-HDL mimetic peptides and a novel D-HDL mimetic peptide was 
designed. These tools were created to further study the roles of HDL and D-HDL in the respiratory 
and circulatory systems. With these new technologies, the consequences of developing D-HDL 
can be understood, and therapies can be produced to protect the body from this pathological 
condition.  
Chapter II investigates the role of HDL in the pulmonary inflammatory response to LPS. 
It was suggested that the inhibition of chemotactic potential, and the observed suppression of the 
inflammatory response, is the result of HDL taking up cholesterol from alveolar macrophages to 
reduce their inflammatory response. It has already been reported that HDL reducing the lipid load 
of monocytes/macrophages, and altering their lipid rafts, reduces their inflammatory response (47). 
It is likely this occurred in the lungs when mice were pretreated with HDL. Once mice received 
LPS exposure their alveolar macrophages may have already had a reduced lipid load, or HDL was 
still passing through circulation and taking up cholesterol after exposure. SR-BI was the only 
lipoprotein receptor shown to be upregulated by HDL at the early time point, 2 hours after 
exposure. Increased expression of ABCG1/ABCA1 by HDL was not observed in this report, but 





ABCG1/ABCA1 transcription will have allowed for increased cholesterol uptake from 
macrophages to occur, thus attenuating the inflammatory response of alveolar macrophages.  
Transcription of ABCG1 and ABCA1 can be activated by liver X receptor (LXR) which is 
known to be activated by physiologic sterol ligands (e.g. oxysterols, cholesterol intermediates 
(193, 194)). Also, LXR agonist supplementation has been reported to decrease human PMN 
chemotaxis to IL-8 (the human analog to MIP-2/KC) (195), as well as knocking in LXR has been 
shown to protect mice from acute lung injury from intranasally instilled LPS (196). There is a clear 
effect of LXR on PMN chemotaxis (197), however the mechanism is unclear. It is possible 
increased LXR leads to decreased CXCR2, preventing PMN migration towards MIP-2/KC. 
Because LXR can be activated by sterol ligands, increased levels of alveolar macrophage 
cholesterol may correlate with an increased expression of the ABCG1, and ABCA1 as part of the 
inflammatory response to LPS.  
HDL may serve one of two purposes in the observed inflammatory response to LPS. First 
HDL may decrease inflammation by decreasing cholesterol concentrations in lung tissue, and thus 
decreasing activation of LXR and lipoprotein receptor transcription after 24 hours. Second, HDL 
can serve as an LXR agonist, possibly by acting directly on circulating PMNs. This would decrease 
PMN chemotaxis towards any MIP-2/KC secreted in the lungs, possibly by inhibiting CXCR2 
surface display. Also, increased LXR would increase the transcription of ABCG1 and ABCA1 
which we’ve proposed would consequently lead to decreased MIP-2/KC secretion. This two-fold 
impact of HDL on CXCR2 and MIP-2/KC would then considerably inhibit PMN chemotaxis, 
which would explain the decreased pulmonary neutrophilia observed. This is a novel application 





In chapter III, a model was developed to assess the functional capabilities of HDL and D-
HDL mimetic peptides. Then a D-HDL mimetic peptide was designed by increasing the 
susceptibility of L-4F to oxidation. HOCl was chosen as the oxidizing agent to maintain 
physiological relevance. HDL is most commonly oxidized by MPO in the body because of the 
tendency for HDL and MPO to accumulate in atherosclerotic plaques (103). MPO produces HOCl 
and has been found to oxidize several different sites of apoA-I to make it dysfunctional (190, 198-
200). Originally, it was intended to use the enzymatic reaction of MPO with H2O2 and NaCl to 
produce HOCl and oxidize L-2W. However, it quickly became understood that analyzing the 
oxidation of the mimetic peptide would be complicated because of the size of MPO compared to 
L-2W. Oxidation was intended to be verified by recording ultraviolet light visual 
spectrophotometry, circular dichroism, and matrix assisted laser desorption/ionization time of 
flight mass spectrometry (MALDI-TOF) measurements of the peptides. These measurements 
would require the filtration of MPO and the other substrates out of solution after peptide oxidation, 
otherwise observation of the peptide would be obscured by the large enzyme. This additional step 
simply added an unnecessary complication to the procedure since the oxidative interaction is solely 
between HOCl and apoA-I, with MPO only producing HOCl. The intention of developing a D-
HDL mimetic peptide was to create a simple tool to be used to study the more complicated 
consequences of D-HDL in pulmonary diseases. Therefore, simply incubating L-2W with HOCl 
was decided to be the optimal method of oxidation. By creating a simple and reproducible model 
for evaluating peptide function, and engineering a novel D-HDL mimetic peptide, valuable 
research can be conducted to understand the complications of D-HDL.  
In conclusion, HDL plays a critical role in the pulmonary inflammatory response, and a D-





Understanding the ability of HDL to suppress the inflammatory response of alveolar macrophages 
highlights the possible ramifications of D-HDL. It is possible D-HDL does not have the ability to 
suppress the inflammatory response. This could lead to more severe pulmonary injury in subjects 
suffering from obesity or diabetes because of a compromised immune system. More research needs 
to be conducted to understand how exactly D-HDL fails to match up to HDL. The D-HDL mimetic 
peptide designed here can be used to conduct this research. Also, the model for evaluating peptide 
function can also be used to assess other D-HDL mimetic peptides that replicate the other types of 
endogenous D-HDL. Overall, this research contributes to the scientific fields of pulmonary 
immunology, cardiovascular health, and lipid research to assist in the medical fields of pulmonary 




Future work may be aimed at further understanding the mechanisms of HDL’s anti-
inflammatory role, and how that is perturbed in D-HDL. This research was primarily conducted to 
elucidate what the role is of HDL in the lungs, and to create a tool for studying D-HDL. HDL has 
been shown to suppress production of inflammatory cytokines, chemokines, and to reduce injury. 
However, there has been little work demonstrating the mechanism of how HDL influences those 
responses. Likewise, there has been even less work on how that influence is altered when HDL 
becomes dysfunctional. The goal would be to identify therapeutic targets encouraging the 
protective effects of HDL and inhibiting the deleterious effects of D-HDL.  
Dependency of HDL’s anti-inflammatory response on lipoprotein receptors could be 
further studied. Here we observed the influence of HDL on lipoprotein receptor expression, so it 





lipoprotein receptors were genetically removed or pharmacologically inhibited. Alveolar 
macrophage specific inhibition of SR-BI could be used to determine the direct interaction point of 
HDL with the pulmonary immune system. It has been reported here that HDL increases SR-BI 
expression 2 hours after LPS exposure, and suppresses its expression 24 hours after LPS exposure. 
It has been proposed that HDL inhibits alveolar macrophage inflammation by reducing 
intracellular cholesterol concentration by transporting cholesterol through SR-BI. Therefore, if 
SR-BI was abolished, alveolar macrophage inflammation would hypothetically increase. 
Investigating the intracellular cholesterol of alveolar macrophages in SR-BI deficient models could 
elucidate the mechanism of HDL’s anti-inflammatory role in the lung. 
The ability of L-4F, and oxL-2W to suppress the pulmonary immune response is another 
area that could be further studied. L-4F has been shown to be suppress the inflammatory response 
to LPS in some models (80, 81). However, there has been no report on the influence of a D-HDL 
mimetic peptide on the pulmonary immune response. An interesting study would be to genetically 
knock out apoA-I, and then administer either L-4F or oxL-2W, or a ratio of the two, and observe 
the inflammatory response of the lungs to LPS. This would first clarify the therapeutic potential 
of L-4F in the face of developed D-HDL, and second could highlight how exactly the pulmonary 
immune system is compromised when D-HDL is present. Presently, there is no good model for 
evaluating the presence of D-HDL via genetic knock out. SR-BI or apoE deficiencies are potential 
options, but because of their widespread necessity throughout the body, expanding beyond the role 
of HDL, it would be impossible to discern between phenotypes of obesity (201), Alzheimer’s 
(202), dyslipidemia (203, 204), or immune suppression (129) and D-HDL.  
Other possibilities exist for further research around the role of HDL and D-HDL in the 





clinical relevance revolving around these lipoproteins. Continued research on the influence of 
HDL on migrating PMNs, endothelial cell inflammation, epithelial cell inflammation and the 
connection to surfactant secretion are all areas that are understudied. Consequently, the impact of 
D-HDL on each of these areas needs to be evaluated if we are to attempt to reduce the drastic 
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